Search alternatives:
teer decrease » greater decrease (Expand Search)
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
11941
-
11942
-
11943
-
11944
-
11945
-
11946
-
11947
-
11948
MOLECULAR FEATURES OF TRIPLE NEGATIVE BREAST CANCER STEM CELLS: A GENE EXPRESSION PROFILING ANALYSIS OF MDA-MB-231 CELLS
Published 2021“…Triple negative breast cancer (TNBC) is a chemoresistant subtype of female breast tumors. …”
Get full text
-
11949
Data Sheet 7_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf
Published 2025“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”
-
11950
Data Sheet 6_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf
Published 2025“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”
-
11951
Data Sheet 1_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf
Published 2025“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”
-
11952
Data Sheet 3_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf
Published 2025“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”
-
11953
Data Sheet 8_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf
Published 2025“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”
-
11954
Data Sheet 4_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf
Published 2025“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”
-
11955
Data Sheet 5_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf
Published 2025“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”
-
11956
Data Sheet 2_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf
Published 2025“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”
-
11957
-
11958
-
11959
-
11960